EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische Studie

Phase 3 Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis

Bruce C Trapnell iD, Yoshikazu Inoue iD, Francesco Bonella iD, Tisha Wang, Cormac McCarthy, Toru Arai, Keiichi Akasaka, Francesca Mariani, Nesrin Mogulkoc, Jin Woo Song, Tomohisa Baba, Stephane Jouneau und 13 weitere

New England Journal of Medicine · 21.08.2025 · 393 (8) · 764-773

DOI: 10.1056/nejmoa2410542 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 21.08.2025. Verfasst von Bruce C Trapnell und 24 weiteren Autor:innen. Beteiligte Einrichtung: Translational Pulmonary Science Center, Cincinnati Children's Hospital Medical Center, Cincinnati. Hauptthemen laut MEDLINE: Autoimmune Diseases, Granulocyte-Macrophage Colony-Stimulating Factor, Pulmonary Alveolar Proteinosis. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: Savara Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Autoimmune DiseasesGranulocyte-Macrophage Colony-Stimulating FactorPulmonary Alveolar ProteinosisAdultFemaleHumansMaleMiddle AgedAdministration, InhalationDouble-Blind MethodPulmonary Diffusing CapacityQuality of LifeRecombinant ProteinsSeverity of Illness Index

Substanzen

Granulocyte-Macrophage Colony-Stimulating FactorRecombinant Proteinsmolgramostim

Autor:innen und Institutionen

  • Translational Pulmonary Science Center, Cincinnati Children's Hospital Medical Center, Cincinnati.
  • Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Internal Medicine, University of Cincinnati, Cincinnati.
  • Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati.
  • Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, Osaka, Japan.
  • Internal Medicine, Osaka Anti-Tuberculosis Association, Osaka Fukujuji Hospital, Osaka, Japan.
  • Center for Interstitial and Rare Lung Diseases, Pneumology Department, Ruhrlandklinik University Hospital, University of Duisburg-Essen, Essen, Germany.

ORCID-Profile: Bruce C Trapnell, Yoshikazu Inoue, Francesco Bonella

Förderung

  • Savara Inc.

Zitieren

APA

Trapnell, B. C., Inoue, Y., Bonella, F., Wang, T., McCarthy, C., Arai, T., Akasaka, K., Mariani, F., Mogulkoc, N., Song, J. W., Baba, T., Jouneau, S., Numakura, T., Öcal, N., Mihaltan, F., Ataya, A., Bendstrup, E., Campo, I., Carey, B., …, & IMPALA-2 Trial Investigators (2025). Phase 3 Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis. New England Journal of Medicine, 393(8), 764-773. https://doi.org/10.1056/nejmoa2410542

Vancouver

Trapnell BC, Inoue Y, Bonella F, Wang T, McCarthy C, Arai T, et al. Phase 3 Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis. New England Journal of Medicine. 2025;393(8):764-773. doi:10.1056/nejmoa2410542

BibTeX
@article{Trapnell2025,
  author = {Trapnell, Bruce C and Inoue, Yoshikazu and Bonella, Francesco and Wang, Tisha and McCarthy, Cormac and Arai, Toru and Akasaka, Keiichi and Mariani, Francesca and Mogulkoc, Nesrin and Song, Jin Woo and Baba, Tomohisa and Jouneau, Stephane and Numakura, Tadahisa and Öcal, Nesrin and Mihaltan, Florin and Ataya, Ali and Bendstrup, Elisabeth and Campo, Ilaria and Carey, Brenna and Arena, Ross and Robinson, Brian and Fleming, Rosanna and Wasfi, Yasmine and Pratt, Raymond and IMPALA-2 Trial Investigators, IMPALA-2 Trial Investigators},
  title = {Phase 3 Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis},
  journal = {New England Journal of Medicine},
  year = {2025},
  volume = {393},
  number = {8},
  pages = {764--773},
  doi = {10.1056/nejmoa2410542}
}
Kostenlos starten →